Retrospective Cohort Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2021; 27(40): 6927-6938
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6927
Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B
Xiu-Mei Chi, Xiao-Mei Wang, Zhong-Feng Wang, Rui-Hong Wu, Xiu-Zhu Gao, Hong-Qin Xu, Yan-Hua Ding, Jun-Qi Niu
Xiu-Mei Chi, Xiao-Mei Wang, Zhong-Feng Wang, Rui-Hong Wu, Xiu-Zhu Gao, Hong-Qin Xu, Jun-Qi Niu, Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Xiu-Mei Chi, Yan-Hua Ding, Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Chi XM contributed to design and data analysis and drafted the manuscript; Wang XM contributed to data analysis and critically revised the manuscript; Wang ZF, Wu RH, Gao XZ and Xu HQ contributed to data acquisition and analysis; Ding YH critically revised the manuscript; Niu JQ contributed to the conception and critically revised the manuscript; All authors read and approved the final manuscript.
Supported by National Science and Technology Major Project, No. 2017ZX10302201, No. 2017ZX09304004 and No. 2014ZX10002002; and National Program on Key Basic Research Project (973 Program), No. 2015CB554304.
Institutional review board statement: This study was approved by the ethics committee of the First Hospital of Jilin University.
Informed consent statement: Informed consent was obtained from each patient for the original trials, with clauses for possibly secondary analyses. The original studies were registered (ClinicalTrials.gov NCT03509688 and NCT03546530).
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Qi Niu, MD, PhD, Academic Research, Dean, Director, Doctor, Professor, Research Scientist, Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. junqiniu@jlu.edu.cn
Received: March 11, 2021
Peer-review started: March 11, 2021
First decision: April 5, 2021
Revised: May 6, 2021
Accepted: September 1, 2021
Article in press: September 1, 2021
Published online: October 28, 2021
ARTICLE HIGHLIGHTS
Research background

Quantitative hepatitis B core-related antigen (qHBcrAg) had a better correlation with intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) than either HBV DNA or hepatitis B e antigen (HBeAg).

Research motivation

Data are still lacking for the widespread clinical application of qHBcrAg.

Research objectives

This study aimed to investigate the serum qHBcrAg levels in patients with chronic hepatitis B (CHB) and to assess the correlation of serum qHBcrAg with pregenomic RNA (pgRNA), cccDNA, and HBeAg seroconversion.

Research methods

This was a secondary analysis of patients who underwent percutaneous liver biopsy in two multicenter, randomized, controlled clinical trials. Serum qHBcrAg, pgRNA, HBV DNA, hepatitis B core antigen, and HBeAg and liver cccDNA, and HBV DNA were measured. The correlations of serum qHBcrAg with other biomarkers were tested.

Research results

Serum qHBcrAg levels were positively associated with pgRNA (r = 0.597, P < 0.0001) and cccDNA (r = 0.527, P < 0.0001) levels. HBcrAg predicted HBeAg seroconversion, with an area under the receiver operating characteristics curve of 0.788 at 24 wk and 0.825 at 48 wk.

Research conclusions

Serum HBcrAg levels correlated with HBV virological markers and could be used to predict HBeAg seroconversion.

Research perspectives

Serum qHBcrAg might be used in the clinical setting to monitor intrahepatic HBV status and determine the long-term prognosis of patients with CHB.